Phathom Pharmaceuticals (PHAT) vs REGENXBIO (RGNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
REGENXBIO (RGNX) has outperformed Phathom Pharmaceuticals (PHAT) over the past year, losing 33.8% versus a loss of 35.5%. Over five years, RGNX leads with a -77.5% price change compared with -78.1% for PHAT. Phathom Pharmaceuticals is the larger company by market cap ($576.8 million vs $534.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PHAT | RGNX |
|---|---|---|
| Share price | $7.13 | $8.09 |
| Market cap | $576.82M | $534.05M |
| 1-day change | +4.70% | +6.52% |
| YTD return | -57.02% | -43.82% |
| 1-year return | -35.48% | -33.80% |
| 5-year return | -78.07% | -77.50% |
| Forward P/E | 6.62 | — |
| EPS (TTM) | $-1.26 | $-3.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.31 | $16.19 |
| 52-week low | $6.52 | $5.46 |
| Distance from 52-week high | -61.06% | -50.03% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +186.82% | +191.47% |
| Average volume | 1.38M | 1.53M |
| Shares outstanding | 80.90M | 66.01M |
| Employees | 371 | 371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Phathom Pharmaceuticals
PHAT stock →Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
Health Care · Biotechnology: Pharmaceutical Preparations · 371 employees
About REGENXBIO
RGNX stock →REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 371 employees
PHAT vs RGNX FAQ
Which is bigger, Phathom Pharmaceuticals or REGENXBIO?
Phathom Pharmaceuticals (PHAT) is larger, with a market capitalization of $576.82M compared with $534.05M for REGENXBIO (RGNX).
Which stock has performed better over the past year, PHAT or RGNX?
RGNX returned -33.80% over the past 12 months, compared with -35.48% for PHAT (price return, excluding dividends). Past performance does not predict future results.
Are Phathom Pharmaceuticals and REGENXBIO in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Phathom Pharmaceuticals and Biotechnology: Biological Products (No Diagnostic Substances) for REGENXBIO.